X0609 4 2026-04-28 1 0001786205 Arcellx, Inc. ACLX 0001670683 Patel Kavita false C/O ARCELLX, INC. 800 BRIDGE PARKWAY REDWOOD CITY CA 94065 true false false false 0 Stock Option (right to buy) 6.66 2026-04-28 4 D 0 27077 D 2031-12-07 Common Stock 27077 0 D Stock Option (right to buy) 15 2026-04-28 4 D 0 20513 D 2032-02-03 Common Stock 20513 0 D Stock Option (right to buy) 37.94 2026-04-28 4 D 0 11459 D 2033-06-14 Common Stock 11459 0 D Stock Option (right to buy) 51.30 2026-04-28 4 D 0 8011 D 2034-05-28 Common Stock 8011 0 D Stock Option (right to buy) 63.68 2026-04-28 4 D 0 9174 D 2035-05-29 Common Stock 9174 0 D Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. /s/ Michelle Gilson, as Attorney-in-Fact 2026-04-28